Search

Corvus Pharmaceuticals Inc

Ouvert

13.13 5.89

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.35

Max

13.18

Chiffres clés

By Trading Economics

Revenu

-4.3M

-18M

BPA

-0.19

Employés

37

EBITDA

-5.3M

-17M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+137.52% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-21M

1.1B

Ouverture précédente

7.24

Clôture précédente

13.13

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 sept. 2026, 23:56 UTC

Revvity Inc is trading modestly higher in after-market hours, positioned above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:56 UTC

Correlated Moves

Eversource Energy is advancing in after-market hours, influenced by OGE Energy's gains earlier in the session, though it remains below its 20-day moving average.

21 sept. 2026, 23:56 UTC

Owens Corning is trading modestly higher in after-market hours, recovering from a recent trend of six consecutive sessions ending lower.

21 sept. 2026, 23:56 UTC

Ameriprise Financial Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

21 sept. 2026, 23:56 UTC

Pool Corp is trading modestly higher in after-market hours following a decline in the Chicago Fed National Activity Index for August, reflecting slower economic growth.

21 sept. 2026, 23:55 UTC

Chimera Investment Corp is trading roughly flat in after-market hours, about 2.48% below its 20-day moving average.

21 sept. 2026, 23:55 UTC

Lamb Weston Holdings Inc is trading modestly lower in after-market hours, continuing the earlier session's weakness and remaining below its 20-day moving average.

21 sept. 2026, 23:55 UTC

Ziff Davis Inc declined during after-market hours on Monday, influenced by broader economic slowdown signals, despite remaining above its 20-day moving average.

21 sept. 2026, 23:55 UTC

Old Republic International Corp is trading modestly higher in after-market hours, recovering slightly after a series of declines over the previous five sessions.

21 sept. 2026, 23:55 UTC

Carlyle Group Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

21 sept. 2026, 23:55 UTC

Mitek Systems Inc is up in after-market trading, reaching a peak despite remaining below its 20-day moving average amid slowing economic growth signals.

21 sept. 2026, 23:55 UTC

Truist Financial Corp is declining in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

21 sept. 2026, 23:55 UTC

Darling Ingredients Inc's stock is trading modestly higher in after-market hours, despite a decline in the Chicago Fed National Activity Index for August.

21 sept. 2026, 23:55 UTC

Solaredge Technologies Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:55 UTC

Booking Holdings Inc. is trading modestly higher in after-market hours following Monday's close, despite remaining significantly below its 20-day moving average.

21 sept. 2026, 23:55 UTC

OraSure Technologies Inc. is trading modestly higher in after-market hours, marking its eighth consecutive session of gains while remaining above its 20-day moving average.

21 sept. 2026, 23:55 UTC

Revolve Group Inc. is trading roughly flat in after-market hours, fluctuating within a range amid economic growth concerns from the Chicago Fed National Activity Index.

21 sept. 2026, 23:52 UTC

News

Boeing Co. has secured two defense contracts worth $41.5 million, while shares have declined slightly in after-market trading, remaining near the lower end of their one-month range.

21 sept. 2026, 23:52 UTC

Yelp Inc. is declining in after-market trading, remaining significantly below its 20-day moving average and continuing a trend of lower daily closes.

21 sept. 2026, 23:51 UTC

Cathay General Bancorp is trading modestly higher in after-market hours, recovering from a slight dip and reaching a peak cumulative return of nearly 1%.

21 sept. 2026, 23:51 UTC

Janus International Group Inc has advanced modestly in after-market trading, continuing a pattern of strength observed throughout the session.

21 sept. 2026, 23:51 UTC

CoStar Group Inc rebounded in after-market trading, showing a cumulative return above its prior close despite remaining below its 20-day moving average.

21 sept. 2026, 23:51 UTC

Cooper Companies Inc is trading modestly higher during after-market hours, despite a significant decline over the past month and trading below its 20-day moving average.

21 sept. 2026, 23:51 UTC

Social Media

Rocket Lab Corp's stock rises in after-market trading following Cantor Fitzgerald's bullish note, reiterating a $122 price target amid successful launches and an upcoming acquisition.

21 sept. 2026, 23:51 UTC

Cabaletta Bio Inc saw notable gains in after-market trading, recovering from a low return shortly after the market closed to a higher return by late session.

21 sept. 2026, 23:51 UTC

Molson Coors Beverage Co sees a modest increase in after-market trading, reaching its highest cumulative return since Monday's close, despite being below its 20-day moving average.

21 sept. 2026, 23:51 UTC

Allstate Corp is seeing notable upward movement in after-market trading, recovering from six consecutive sessions of lower finishes.

21 sept. 2026, 23:51 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:51 UTC

OGE Energy Corp is trading modestly higher in after-market hours, following notable upward movement from its previous close, despite remaining below its 20-day moving average.

21 sept. 2026, 23:51 UTC

United Therapeutics Corp is trading modestly higher in after-market hours, recovering from an initial dip and showing volatility since Monday's close.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

137.52% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD  137.52%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.